Table of Contents
International Journal of Molecular Imaging
Volume 2012 (2012), Article ID 464810, 7 pages
http://dx.doi.org/10.1155/2012/464810
Research Article

111Indium Labelling of Recombinant Activated Coagulation Factor VII: In Vitro and Preliminary In Vivo Studies in Healthy Rats

1Institute of Biomedical Sciences, Faculty of Health Sciences, University of Copenhagen, DK-2200, Copenhagen, Denmark
2Faculty of Medical Laboratory Science, Metropolitan University College, DK-2200, Copenhagen, Denmark
3Cluster for Molecular Imaging, Faculty of Health Sciences, University of Copenhagen, DK-2200, Copenhagen, Denmark
4Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, University of Copenhagen, DK-2100, Copenhagen, Denmark

Received 7 September 2011; Revised 28 October 2011; Accepted 28 October 2011

Academic Editor: Weibo Cai

Copyright © 2012 Amarnadh Nalla et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. NovoSeven® RT Coagulation Factor VIIa (Recombinant), Novo Nordisk Inc., August 2010, http://www.NovoSevenRT.com.
  2. N. S. Key, L. M. Aledort, D. Beardsley et al., “Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors,” Thrombosis and Haemostasis, vol. 80, no. 6, pp. 912–918, 1998. View at Google Scholar · View at Scopus
  3. A. Villar, S. Aronis, M. Morfini et al., “Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven®) in children vs. adults with haemophilia A,” Haemophilia, vol. 10, no. 4, pp. 352–359, 2004. View at Google Scholar · View at Scopus
  4. M. Berrettini, G. Mariani, M. Schiavoni et al., “Pharmacokinetic evaluation of recombinant, activated factor VII in patients with inherited factor VII deficiency,” Haematologica, vol. 86, no. 6, pp. 640–645, 2001. View at Google Scholar · View at Scopus
  5. S. Arkin, H. A. Cooper, J. J. Hutter et al., “Activated recombinant human coagulation factor VII therapy for intracranial hemorrhage in patients with hemophilia A or B with inhibitors. Results of the novoseven emergency-use program,” Haemostasis, vol. 28, no. 2, pp. 93–98, 1999. View at Google Scholar
  6. S. Arkin, F. Blei, J. Fetten et al., “Human coagulation factor FVIIa (recombinant) in the management of limb- threatening bleeds unresponsive to alternative therapies: results from the NovoSeven® emergency-use programme in patients with severe haemophilia or with acquired inhibitors,” Blood Coagulation and Fibrinolysis, vol. 11, no. 3, pp. 255–259, 2000. View at Google Scholar · View at Scopus
  7. M. C. Poon, C. Demers, F. Jobin, and J. W. Y. Wu, “Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia,” Blood, vol. 94, no. 11, pp. 3951–3953, 1999. View at Google Scholar · View at Scopus
  8. J. Chen, A. Bierhaus, S. Schiekofer et al., “Tissue factor—a receptor involved in the control of cellular properties, including angiogenesis,” Thrombosis and Haemostasis, vol. 86, no. 1, pp. 334–345, 2001. View at Google Scholar · View at Scopus
  9. J. H. Morrissey, “Tissue factor: an enzyme cofactor and a true receptor,” Thrombosis and Haemostasis, vol. 86, no. 1, pp. 66–74, 2001. View at Google Scholar · View at Scopus
  10. P. M. Fernandez and F. R. Rickles, “Tissue factor and angiogenesis in cancer,” Current Opinion in Hematology, vol. 9, no. 5, pp. 401–406, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Guo, H. Zhou, Y. Wu et al., “Involvement of ERK1/2/NF-κB signal transduction pathway in TF/FVIIa/PAR2-induced proliferation and migration of colon cancer cell SW620,” Tumor Biology, vol. 32, no. 5, pp. 921–930, 2011. View at Publisher · View at Google Scholar · View at PubMed
  12. Z. Ma, T. Zhang, R. Wang et al., “Tissue factor-factor VIIa complex induces epithelial ovarian cancer cell invasion and metastasis through a monocytes-dependent mechanism,” International Journal of Gynecological Cancer, vol. 21, no. 4, pp. 616–624, 2011. View at Publisher · View at Google Scholar · View at PubMed
  13. M. Shoji, A. Sun, W. Kisiel et al., “Targeting tissue factor-expressing tumor angiogenesis and tumors with EF24 conjugated to factor VIIa,” Journal of Drug Targeting, vol. 16, no. 3, pp. 185–197, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. E. Cocco, J. Varughese, N. Buza et al., “Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor,” Clinical and Experimental Metastasis, vol. 28, no. 7, pp. 689–700, 2011. View at Google Scholar
  15. E. Cocco, J. Varughese, N. Buza et al., “Expression of Tissue factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix: implications for immunotherapy with hI-con1, a factor VII-IgGFaacchimeric protein targeting tissue factor,” BMC Cancer, vol. 11, article 263, 2011. View at Publisher · View at Google Scholar · View at PubMed
  16. J. Duanmu, J. Cheng, J. Xu, C. J. Booth, and Z. Hu, “Effective treatment of chemoresistant breast cancer in vitro and in vivo by a factor VII-targeted photodynamic therapy,” British Journal of Cancer, vol. 104, no. 9, pp. 1401–1409, 2011. View at Publisher · View at Google Scholar · View at PubMed
  17. R. S. Kasthuri, M. B. Taubman, and N. Mackman, “Role of tissue factor in cancer,” Journal of Clinical Oncology, vol. 27, no. 29, pp. 4834–4838, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. G. M. Lanza, D. R. Abendschein, C. S. Hall et al., “In vivo molecular imaging of stretch-induced tissue factor in carotid arteries with ligand-targeted nanoparticles,” Journal of the American Society of Echocardiography, vol. 13, no. 6, pp. 608–614, 2000. View at Google Scholar · View at Scopus
  19. S. Falati, P. Gross, G. Merrill-skoloff, B. C. Furie, and B. Furie, “Real time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse,” Nature Medicine, vol. 8, no. 10, pp. 1175–1181, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. M. Marignani, S. Angeletti, L. Filippi, R. Danieli, and O. Schillaci, “Occult and obscure bleeding, iron deficiency anemia and other gastrointestinal stories (Review),” International Journal of Molecular Medicine, vol. 15, no. 1, pp. 129–135, 2005. View at Google Scholar · View at Scopus
  21. C. P. Dooley, A. W. Larson, N. H. Stace et al., “Double-contrast barium meal and upper gastrointestinal endoscopy. A comparative study,” Annals of Internal Medicine, vol. 101, no. 4, pp. 538–545, 1984. View at Google Scholar
  22. G. M. Currie, H. Kiat, and J. M. Wheat, “Scintigraphic evaluation of acute lower gastrointestinal hemorrhage: current status and future directions,” Journal of Clinical Gastroenterology, vol. 45, no. 2, pp. 92–99, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. R. K. Smith and G. Arterburn, “Detection of localization of gastrointestinal bleeding using Tc-99m-pyrophosphate in vivo labeled red blood cells,” Clinical Nuclear Medicine, vol. 5, no. 2, pp. 55–60, 1980. View at Google Scholar · View at Scopus
  24. G. G. Winzelberg, K. A. McKusick, H. W. Strauss, A. C. Waltman, and A. J. Greenfield, “Evaluation of gastrointestinal bleeding by red blood cells labeled in vivo with technetium-99m,” Journal of Nuclear Medicine, vol. 20, no. 10, pp. 1080–1086, 1979. View at Google Scholar · View at Scopus
  25. J. Madsen, J. Kristensen, O. Olsen et al., “Recombinant coagulation factor VIIa labelled with the fac- 99mTc(CO)3-core: synthesis and in vitro evaluation of a putative new radiopharmaceutical for imaging in acute bleeding lesion,” Journal of Labelled Compounds and Radiopharmaceuticals, vol. 54, no. 4, pp. 214–219, 2011. View at Publisher · View at Google Scholar
  26. D. J. Hnatowich, W. W. Layne, R. L. Childs et al., “Radioactive labeling of antibody: a simple and efficient method,” Science, vol. 220, no. 4597, pp. 613–615, 1983. View at Google Scholar
  27. L. Camera, S. Kinuya, K. Garmestani et al., “Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies,” Journal of Nuclear Medicine, vol. 35, no. 5, pp. 882–889, 1994. View at Google Scholar · View at Scopus
  28. M. S. Cooper, E. Sabbah, and S. J. Mather, “Conjugation of chelating agents to proteins and radiolabeling with trivalent metallic isotopes,” Nature Protocols, vol. 1, no. 1, pp. 314–317, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. J. M. Esteban, J. Schlom, O. A. Gansow et al., “New method for the chelation of Indium-111 to monoclonal antibodies: biodistribution and imaging of athymic mice bearing human colon carcinoma xenografts,” Journal of Nuclear Medicine, vol. 28, no. 5, pp. 861–870, 1987. View at Google Scholar
  30. S. J. Mather, D. M. Tolley, and G. W. White, “Labelling monoclonal antibodies with Yttrium-90,” European Journal of Nuclear Medicine, vol. 15, no. 6, pp. 307–312, 1989. View at Google Scholar · View at Scopus
  31. S. M. P. Andrew, A. C. Perkins, M. V. Pimm, and R. W. Baldwin, “A comparison of iodine and indium labelled anti CEA intact antibody, F(ab)2 and Fab fragments by imaging tumour xenografts,” European Journal of Nuclear Medicine, vol. 13, no. 11, pp. 598–604, 1988. View at Google Scholar · View at Scopus
  32. K. Tahtis, F. T. Lee, F. E. Smyth et al., “Biodistribution properties of 111indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F(ab')2 constructs in a breast carcinoma xenograft model,” Clinical Cancer Research, vol. 7, no. 4, pp. 1061–1072, 2001. View at Google Scholar · View at Scopus
  33. D. J. Hnatowich, W. W. Layne, and R. L. Childs, “The preparation and labeling of DTPA-coupled albumin,” International Journal of Applied Radiation and Isotopes, vol. 33, no. 5, pp. 327–332, 1982. View at Publisher · View at Google Scholar · View at Scopus
  34. S. S. Zoghbi, R. D. Neumann, and A. A. Gottschalk, “A modified procedure for rapid labelling of low concentrations of bioactive proteins with indium-111,” International Journal of Nuclear Medicine and Biology, vol. 12, no. 3, pp. 159–166, 1985. View at Google Scholar · View at Scopus
  35. C. H. Paik, M. A. Ebbert, P. R. Murphy et al., “Factors influencing DTPA conjugation with antibodies by cyclic DTPA anhydride,” Journal of Nuclear Medicine, vol. 24, no. 12, pp. 1158–1163, 1983. View at Google Scholar · View at Scopus
  36. A. Nalla, I. Buch, and B. Hesse, “Easy and efficient 111indium labeling of long-term stored DTPA-conjugated protein,” Current Radiopharmaceuticals, vol. 4, no. 1, pp. 1–4, 2011. View at Publisher · View at Google Scholar
  37. E. C. Ellison, W. J. Schirmer, J. O. Olsen et al., “Localization of neuroendocrine tumors using somatostatin receptor imaging with Indium-111-pentetreotide (octreoscan),” Cancer Control, vol. 4, no. 1, pp. 35–39, 1997. View at Google Scholar · View at Scopus
  38. B. R. Davidson, J. Babich, H. Young et al., “The effect of circulating antigen and radiolabel stability on the biodistribution of an indium labelled antibody,” British Journal of Cancer, vol. 64, no. 5, pp. 850–856, 1991. View at Google Scholar · View at Scopus
  39. T. Kornfelt, E. Persson, and L. Palm, “Oxidation of methionine residues in coagulation factor VIIa,” Archives of Biochemistry and Biophysics, vol. 363, no. 1, pp. 43–54, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. S. Soenderkaer, J. F. Carpenter, M. van de Weert, L. L. Hansen, J. Flink, and S. Frokjaer, “Effects of sucrose on rFVIIa aggregation and methionine oxidation,” European Journal of Pharmaceutical Sciences, vol. 21, no. 5, pp. 597–606, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. M. K. Thomsen, V. Diness, P. Nilsson, S. N. Rasmussen, T. Taylor, and U. Hedner, “Pharmacokinetics of recombinant factor VIIa in the rat—a comparison of bio-, immuno- and isotope assays,” Thrombosis and Haemostasis, vol. 70, no. 3, pp. 458–464, 1993. View at Google Scholar · View at Scopus
  42. C. Milsom and J. Rak, “Tissue factor and cancer,” Pathophysiology of Haemostasis and Thrombosis, vol. 36, no. 3-4, pp. 160–176, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. F. R. Rickles, “Mechanisms of cancer-induced thrombosis,” Pathophysiology of Haemostasis and Thrombosis, vol. 35, no. 1-2, pp. P103–P110, 2006. View at Google Scholar · View at Scopus
  44. F. Langer, F. K. Chun, A. Amirkhosravi et al., “Plasma tissue factor antigen in localized prostate cancer: distribution, clinical significance and correlation with haemostatic activation markers,” Thrombosis and Haemostasis, vol. 97, no. 3, pp. 464–470, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. T. A. Hembrough, J. F. Ruiz, B. M. Swerdlow et al., “Identification and characterization of a very low density lipoprotein receptor-binding peptide from tissue factor pathway inhibitor that has antitumor and antiangiogenic activity,” Blood, vol. 103, no. 9, pp. 3374–3380, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. M. E. Bromberg, W. H. Konigsberg, J. F. Madison, A. Pawashe, and A. Garen, “Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 18, pp. 8205–8209, 1995. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Tranholm, Recombinant activated factor VII (rFVIIa) in experimental models of haemostasis, Ph.D. thesis, Faculty of Health Sciences, University of Copenhagen, Denmark, Copenhagen, 2004.